Boris Nikolic - Editas Medicine Independent Director
| EDIT Stock | USD 5.35 0.11 2.01% |
Director
Dr. Boris Nikolic, M.D., is an Independent Director of the company. since August 2015. Dr. Nikolic has served as a member of our board of directors since August 2015. Dr. Nikolic has served as managing partner of investment fund bng0, LLC since February 2015 and has served as Managing Partner of investment fund Biomatics Capital since April 2014. From April 2009 to April 2014, he served as Chief Advisor for Science and Technology to Bill Gates at bgC3, a think tank. From 2002 to 2010, Dr. Nikolic was an assistant professor at Harvard Medical School since 2015.
| Age | 47 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Address | 11 Hurley Street, Cambridge, MA, United States, 02141 |
| Phone | 617 401 9000 |
| Web | https://www.editasmedicine.com |
Editas Medicine Management Efficiency
The company has return on total asset (ROA) of (0.2087) % which means that it has lost $0.2087 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4317) %, meaning that it created substantial loss on money invested by shareholders. Editas Medicine's management efficiency ratios could be used to measure how well Editas Medicine manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.32 in 2024. Return On Capital Employed is likely to drop to -0.41 in 2024. Non Current Liabilities Total is likely to gain to about 115.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 40.9 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Frank Verwiel | Intellia Therapeutics | 55 | |
| Chathaphum Khantiwiriya | Ginkgo Bioworks Holdings | 52 | |
| Deborah Messemer | Allogene Therapeutics | 60 | |
| Terrence Kearney | Vertex Pharmaceuticals | 63 | |
| David Bonderman | Allogene Therapeutics | 75 | |
| Tom Woiwode | Crispr Therapeutics AG | 43 | |
| Simeon George | Crispr Therapeutics AG | 41 | |
| Ali Behbahani | Crispr Therapeutics AG | 40 | |
| Benedict Reichel | Ginkgo Bioworks Holdings | N/A | |
| Fred Cohen | Intellia Therapeutics | 61 | |
| Sirisak Piyathatsikun | Ginkgo Bioworks Holdings | 42 | |
| David Greenway | Vertex Pharmaceuticals | 34 | |
| Suphaphorn Chuasiriphatthana | Ginkgo Bioworks Holdings | 45 | |
| Sangeeta Bhatia | Vertex Pharmaceuticals | 49 | |
| Chaloemphong Mahawanitwong | Ginkgo Bioworks Holdings | 42 | |
| Elaine Ullian | Vertex Pharmaceuticals | 69 | |
| Caroline Dorsa | Intellia Therapeutics | 58 | |
| John DeYoung | Allogene Therapeutics | 55 | |
| Bradley Bolzon | Crispr Therapeutics AG | 56 | |
| Sitthichai Kesornsombat | Ginkgo Bioworks Holdings | 51 | |
| David Altshuler | Vertex Pharmaceuticals | 53 | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.21 |
Editas Medicine Leadership Team
Elected by the shareholders, the Editas Medicine's board of directors comprises two types of representatives: Editas Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Editas. The board's role is to monitor Editas Medicine's management team and ensure that shareholders' interests are well served. Editas Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Editas Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Bitterman, Independent Director | ||
| Alexandra Glucksmann, COO | ||
| John Mendlein, Independent Director | ||
| Boris Nikolic, Independent Director | ||
| Vickesh Myer, CTO | ||
| Douglas Cole, Independent Director | ||
| Andrew Hirsch, Director | ||
| Gilmore MD, CEO President | ||
| Alexis Borisy, Independent Director | ||
| Gerald Cox, Chief Medical Officer | ||
| Gilmore ONeill, CEO President | ||
| James Mullen, Chairman of the Board | ||
| Mark Mullikin, Investor Relations Officer | ||
| Michelle Robertson, Principal CFO | ||
| Harry III, VP Operations | ||
| Eric Ek, Interim CFO, Principal Accounting Officer and Principal Financial Officer | ||
| Baisong MD, Senior Officer | ||
| Andrew Hack, CFO | ||
| Jessica Hopfield, Director | ||
| Linda Burkly, Executive Officer | ||
| Cynthia Collins, Director | ||
| Katrine Bosley, President CEO, Director | ||
| Doug Cole, Independent Director | ||
| Akshay Vaishnaw, Director | ||
| Charles Albright, Chief Scientific Officer | ||
| David Scadden, Director | ||
| Bruce Eaton, Exec Officer | ||
| Cristi Barnett, Corporate Relations | ||
| Charlene JD, Executive Counsel | ||
| David Liu, CoFounder Member | ||
| Mark Shearman, Ex Officer | ||
| Feng Zhang, CoFounder Member | ||
| Linea Aspesi, Executive Officer | ||
| CPA CFA, CFO VP | ||
| George Church, CoFounder Member |
Editas Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Editas Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (1.96) % | ||||
| Operating Margin | (0.40) % | ||||
| Current Valuation | 160.13 M | ||||
| Shares Outstanding | 82.23 M | ||||
| Shares Owned By Insiders | 0.30 % | ||||
| Shares Owned By Institutions | 80.14 % | ||||
| Number Of Shares Shorted | 16.36 M | ||||
| Price To Earning | (7.02) X |
Pair Trading with Editas Medicine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Editas Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will appreciate offsetting losses from the drop in the long position's value.Moving against Editas Stock
| 0.78 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.69 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.56 | ELYM | Eliem Therapeutics | PairCorr |
| 0.48 | XFOR | X4 Pharmaceuticals Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Editas Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Editas Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Editas Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Editas Medicine to buy it.
The correlation of Editas Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Editas Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Editas Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Editas Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Editas Stock analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.02) | Revenue Per Share 1.028 | Quarterly Revenue Growth 8.187 | Return On Assets (0.21) | Return On Equity (0.43) |
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Editas Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.